Correlation of sino-nasal outcome test and nasal polyp score in dupilumab-treated chronic rhinosinusitis with nasal polyps

被引:0
|
作者
Mauthe, Tina [1 ,2 ]
Ryser, Fabio S. [3 ,4 ]
Bruehlmann, Catrin [1 ,2 ]
Yalamanoglu, Ayla [5 ]
Meerwein, Christian [1 ,2 ]
Steiner, Urs C. [3 ,6 ]
Soyka, Michael B. [1 ,2 ]
机构
[1] Univ Zurich, Univ Hosp Zurich, Dept Otorhinolaryngol Head & Neck Surg, Zurich, Switzerland
[2] Univ Zurich, Fac Med, Zurich, Switzerland
[3] Univ Bern, Univ Hosp Bern, Dept Rheumatol & Immunol, Bern, Switzerland
[4] Univ Bern, Grad Sch Hlth Sci, Bern, Switzerland
[5] Univ Zurich, Univ Hosp Zurich, Dept Immunol, Zurich, Switzerland
[6] Univ Bern, Inselspital Bern Univ Hosp, Inst Clin Chem, Bern, Switzerland
关键词
Dupilumab; Chronic rhinosinusitis with nasal polyps; Patient related outcome measures; Nasal polyp score; SNOT; Sinonasal outcome test; COMORBID CHRONIC RHINOSINUSITIS; QUALITY-OF-LIFE; MODERATE; SYSTEM; ASTHMA;
D O I
10.1007/s00405-024-08973-7
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: The alignment between objective scores and patient-reported outcome measures (PROMs) is underexplored. This study aimed to assess changes in Nasal Polyp Score (NPS) and Sino-Nasal Outcome Test (SNOT) scores in chronic rhinosinusitis with nasal polyps (CRSwNP) patients undergoing dupilumab treatment and explore correlations between these scores. Methods: CRSwNP patients received dupilumab therapy for six months. SNOT-20 German Adapted Version (GAV)/SNOT-22 scores were assessed weekly, and NPS was measured at baseline and after one, three, and six months. Correlations were analyzed using Spearman's rank correlation and regression analysis. Results: 69 patients were included. After one, three and six months of dupilumab therapy, SNOT and NPS scores improved significantly. Correlation analysis of SNOT and NPS showed significant correlations only within the nasal subscores, along with a weak trend for SNOT-20. Absolute changes over time lacked significance. However, correlation analysis revealed significant associations between relative changes in SNOT score and NPS, irrespective of timing, and when stratified by baseline NPS of 8, 6, and 4 (r = -0.54, p = 0.01; r = -0.44, p < 0.001; r = -0.7, p < 0.001). This was supported by linear regression modeling, suggesting potential predictive capability of NPS reduction on relative SNOT score improvement. Conclusion: Dupilumab therapy significantly improved subjective and objective CRSwNP scores, exhibiting weak correlations in absolute values for nasal subscores. Furthermore, evidence indicated a correlation between relative changes in SNOT score and NPS, substantiated by predictive capability. This might be due to subjective perception variability, highlighting the suitability of relative change correlation analysis.
引用
收藏
页码:207 / 218
页数:12
相关论文
共 50 条
  • [41] Nasal brushing molecular endotyping distinguishes patients with chronic rhinosinusitis with nasal polyps with better response to dupilumab
    Gayvert, Kaitlyn
    Desrosiers, Martin
    Laidlaw, Tanya M.
    Mannent, Leda P.
    Patel, Kiran
    Horowitz, Julie
    Amin, Nikhil
    Jagerschmidt, Alexandre
    Hamilton, Jennifer D.
    Lim, Wei Keat
    Harel, Sivan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 154 (03) : 619 - 630
  • [42] Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
    Hellings, Peter W.
    Peters, Anju T.
    Chaker, Adam M.
    Heffler, Enrico
    Zhang, Haixin
    Praestgaard, Amy
    Nash, Scott
    Khan, Asif H.
    Siddiqui, Shahid
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Deniz, Yamo
    INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2022, 12 (07) : 958 - 962
  • [43] Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps
    Klimek, L.
    Chaker, A.
    Deitmer, T.
    Plontke, S. K.
    Wollenberg, B.
    Bousquet, J.
    Bachert, C.
    HNO, 2021, 69 (11) : 868 - 877
  • [44] Onset, Maintenance, and Durability of Response with Dupilumab in Chronic Rhinosinusitis with Nasal Polyps
    Bachert, C.
    Khan, A.
    Fokkens, W.
    Hopkins, C.
    Gevaert, P.
    Han, J.
    Hellings, P.
    Lee, S.
    Msihid, J.
    Nash, S.
    Siddiqui, S.
    Jacob-Nara, J.
    Deniz, Y.
    Rowe, P.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [45] Chronic rhinosinusitis with nasal polyps-extension of dupilumab treatment intervals
    Appel, H. M.
    Lochbaum, R.
    Hoffmann, T. K.
    Hahn, J.
    HNO, 2024, 72 (07) : 499 - 503
  • [46] Subcutaneous Dupilumab and Mometasone Furoate Nasal Spray for Chronic Rhinosinusitis With Polyps
    Schneider, John S.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2016, 142 (07) : 698 - 699
  • [47] Efficacy of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Allergic Rhinitis
    Peters, A.
    Wagenmann, M.
    Bernstein, J. A.
    Zhang, H.
    Khan, A. H.
    Nash, S.
    Jacob-Nara, J. A.
    Siddiqui, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [48] Persistent use of dupilumab in adults with asthma or chronic rhinosinusitis with nasal polyps
    Corey, Kristen B.
    Moore, Ryan
    Zuckerman, Autumn D.
    Littlejohn, Monica
    Cahill, Katherine N.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 132 (03) : 390 - 391
  • [49] Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps*
    Kemp, Pieter
    Otten, Josje J.
    Adriaensen, Gwijde F. J. P. M.
    Benoist, Linda B. L.
    Cornet, Marjolein E.
    Hoven, D. Rienk
    Rinia, Bas
    Verkest, Valerie
    Fokkens, Wytske J.
    Reitsma, Sietze
    RHINOLOGY, 2024, 62 (02) : 202 - 207
  • [50] Impact of Overweight on Response to Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps
    Habenbacher, Michael
    Moser, Ulrich
    Abaira, Ahmed
    Tomazic, Peter Valentin
    Kiss, Peter
    Holzmeister, Clemens
    Pock, Jakob
    Walla, Katharina
    Lang, Angelika
    Andrianakis, Alexandros
    NUTRIENTS, 2024, 16 (17)